Levin Capital Strategies L.P. Has $126,000 Holdings in Delcath Systems, Inc. (NASDAQ:DCTH)

Levin Capital Strategies L.P. decreased its position in Delcath Systems, Inc. (NASDAQ:DCTH) by 72.7% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 15,000 shares of the company’s stock after selling 39,969 shares during the period. Levin Capital Strategies L.P. owned about 0.05% of Delcath Systems worth $126,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in DCTH. Rosalind Advisors Inc. boosted its position in shares of Delcath Systems by 155.1% in the second quarter. Rosalind Advisors Inc. now owns 2,650,389 shares of the company’s stock worth $22,184,000 after buying an additional 1,611,561 shares during the period. AIGH Capital Management LLC purchased a new position in Delcath Systems during the 4th quarter valued at about $4,918,000. Worth Venture Partners LLC acquired a new position in shares of Delcath Systems in the 4th quarter valued at about $1,224,000. ADAR1 Capital Management LLC purchased a new stake in shares of Delcath Systems in the fourth quarter worth approximately $962,000. Finally, BVF Inc. IL boosted its holdings in shares of Delcath Systems by 23.1% during the first quarter. BVF Inc. IL now owns 1,202,067 shares of the company’s stock worth $5,734,000 after purchasing an additional 225,918 shares during the period. 61.12% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have issued reports on DCTH shares. StockNews.com downgraded shares of Delcath Systems from a “hold” rating to a “sell” rating in a research report on Monday. HC Wainwright reiterated a “buy” rating and set a $22.00 price objective on shares of Delcath Systems in a report on Tuesday, August 6th. Craig Hallum assumed coverage on Delcath Systems in a research note on Friday, June 28th. They issued a “buy” rating and a $18.00 target price on the stock. Finally, Stephens reaffirmed an “overweight” rating and issued a $25.00 target price on shares of Delcath Systems in a research report on Tuesday, August 6th.

Delcath Systems Trading Up 0.9 %

DCTH stock opened at $9.87 on Wednesday. The firm has a market cap of $274.25 million, a PE ratio of -3.72 and a beta of 0.78. Delcath Systems, Inc. has a 1 year low of $2.25 and a 1 year high of $11.74. The company has a fifty day simple moving average of $8.59 and a 200 day simple moving average of $6.81.

Delcath Systems (NASDAQ:DCTH) last released its quarterly earnings results on Monday, August 5th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.12). Delcath Systems had a negative return on equity of 312.48% and a negative net margin of 474.22%. The company had revenue of $7.77 million for the quarter, compared to the consensus estimate of $5.00 million. During the same quarter last year, the company posted ($0.58) EPS. As a group, analysts forecast that Delcath Systems, Inc. will post -1.33 EPS for the current fiscal year.

Delcath Systems Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.